SRNE
Sorrento Therapeutics, Inc.
SRNE
SRNE
Delisted
SRNE was delisted on the 22nd of February, 2023.
About: Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for the treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody-drug conjugates.
Employees: 799
Financial journalist opinion
Charts implemented using
Lightweight Charts™